Skip to main content

Table 3 Incremental cost-effectiveness analysis (direct medical costs and clinical effects of patients treated with alternatives therapies)

From: Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors

Treatments

Costs*

Costs ▲†

Effectiveness‡

Effectivenessâ–²

ACER**

ICER††

Celecoxib

6,524.6

 

371

 

17.595

 

Nonselective NSAIDs

6,587.4

62.8

274

97

24.033

Dominance

Acetaminophen

7,026.7

502.1

270

101

26.029

Dominance

  1. *Estimated costs by patient (Mexican pesos).
  2. †Incremental costs.
  3. ‡Number of patients with pain control without adverse events.
  4. **Average cost-effectiveness ratio.
  5. ††Incremental cost-effectiveness ratio.
  6. NSAIDs, nonsteroidal anti-inflammatory drugs.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us